Skip to content
2000
Volume 26, Issue 14
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

Amylin is a thirty-seven amino acid peptide hormone that is secreted from the pancreas with insulin. The peptide hormone amylin activates its receptors in the brain to regulate blood glucose and food appetite. Interestingly, the amylin receptor is the heterodimer of the calcitonin receptor (which is the receptor for the peptide hormone calcitonin) and an accessory protein called receptor activity-modifying protein. Amylin receptor activation has emerged as a promising drug target for the treatment of diabetes and obesity. Recent pharmaceutical efforts with amylin receptor activators have focused on developing drugs for the treatment of obesity. Multiple amylin analogs have been tested in pre-clinical settings, and some are currently being tested in clinical trials. For this review, recent research publications and available information regarding drug development targeting amylin receptors were collected. This review summarizes the amylin receptor activators currently being tested in clinical trials for the treatment of obesity. In addition, recent research achievements were demonstrated, such as the introduction of mutations that enhanced receptor affinity/potency and the development of a method for measuring selective amylin receptor activation. Potential issues along with peptide drug development were described, including lipidation to achieve a long-acting property. The combination of an amylin analog and other anti-obesity peptide drugs has demonstrated higher clinical efficacy in reducing body weight than monotherapy. The combination therapy is likely to be the first drug therapy where an amylin analog is used for obesity treatment. In addition, amylin receptor activators may have an adverse effect profile more favorable than that of GLP-1 receptor activators, which could be a potential benefit of amylin receptor activators.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdt/10.2174/0113894501398624250819070004
2025-08-29
2026-02-02

  • From This Site

    /content/journals/cdt/10.2174/0113894501398624250819070004
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Consequences of obesity.2022Available from: https://www.cdc.gov/obesity/basics/consequences.html
  2. Risk factors for obesity.2024Available from: https://www.cdc.gov/obesity/risk-factors/risk-factors.html
  3. ThakerV.V. Genetic and epigenetic causes of obesity.Adolesc. Med. State Art Rev.201728237940530416642
     [Google Scholar]
  4. PaneraN. MandatoC. CrudeleA. BertrandoS. VajroP. AlisiA. Genetics, epigenetics and transgenerational transmission of obesity in children.Front. Endocrinol.202213100600810.3389/fendo.2022.100600836452324
     [Google Scholar]
  5. KumarM. HussainM.S. SonuS.R. RajS. VermaR. SharmaS. SahuS.K. An overview of treatment modalities and management aspects for obesity.Curr. Nutr. Food Sci.202319210511310.2174/1573401318666220527124759
     [Google Scholar]
  6. Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin).2020Available from: https://www.fda.gov/drugs/drug-safety-and-availability/safety-clinical-trial-shows-possible-increased-risk-cancer- weight-loss-medicine-belviq-belviq-xr
  7. JainS. RamanandS. RamanandJ. AkatP. PatwardhanM. JoshiS. Evaluation of efficacy and safety of orlistat in obese patients.Indian J. Endocrinol. Metab.20111529910410.4103/2230‑8210.8193821731866
     [Google Scholar]
  8. GaddeK. Shin Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity.Diabetes Metab. Syndr. Obes.2013613113910.2147/DMSO.S4340323630428
     [Google Scholar]
  9. ShermanMM UngureanuS ReyJA Naltrexone/Bupropion ER (Contrave): Newly approved treatment option for chronic weight management in obese adults.P T201641316417226957883
     [Google Scholar]
  10. GallwitzB. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus.Treat. Endocrinol.20054636137010.2165/00024677‑200504060‑0000516318402
     [Google Scholar]
  11. KimK.S. ParkJ.S. HwangE. ParkM.J. ShinH.Y. LeeY.H. KimK.M. GautronL. GodschallE. PortilloB. GroseK. JungS.H. BaekS.L. YunY.H. LeeD. KimE. AjwaniJ. YooS.H. GülerA.D. WilliamsK.W. ChoiH.J. GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans.Science2024385670743844610.1126/science.adj253738935778
     [Google Scholar]
  12. Menacho-MelgarR DeckerJS HenniganJN LynchMD A review of lipidation in the development of advanced protein and peptide therapeutics.J. Control. Release201929511210.1016/j.jconrel.2018.12.03230579981
     [Google Scholar]
  13. JastreboffA.M. AronneL.J. AhmadN.N. WhartonS. ConneryL. AlvesB. KiyosueA. ZhangS. LiuB. BunckM.C. StefanskiA. Tirzepatide once weekly for the treatment of obesity.N. Engl. J. Med.2022387320521610.1056/NEJMoa220603835658024
     [Google Scholar]
  14. HayD.L. ChenS. LutzT.A. ParkesD.G. RothJ.D. Amylin: Pharmacology, physiology, and clinical potential.Pharmacol. Rev.201567356460010.1124/pr.115.01062926071095
     [Google Scholar]
  15. LutzT.A. Amylinergic control of food intake.Physiol. Behav.200689446547110.1016/j.physbeh.2006.04.00116697020
     [Google Scholar]
  16. YoungA. Inhibition of food intake.Adv. Pharmacol.200552799810.1016/S1054‑3589(05)52005‑216492542
     [Google Scholar]
  17. YoungA. Inhibition of gastric emptying.Adv. Pharmacol.2005529912110.1016/S1054‑3589(05)52006‑416492543
     [Google Scholar]
  18. YoungA. Inhibition of glucagon secretion.Adv. Pharmacol.20055215117110.1016/S1054‑3589(05)52008‑816492545
     [Google Scholar]
  19. ChiuC. SinghS. de PabloJ.J. Effect of proline mutations on the monomer conformations of amylin.Biophys. J.201310551227123510.1016/j.bpj.2013.07.02924010666
     [Google Scholar]
  20. McQueenJ. Pramlintide acetate.Am. J. Health Syst. Pharm.200562222363237210.2146/ajhp05034116278328
     [Google Scholar]
  21. AronneL. FujiokaK. ArodaV. ChenK. HalsethA. KestyN.C. BurnsC. LushC.W. WeyerC. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: A phase 2, randomized, placebo-controlled, dose-escalation study.J. Clin. Endocrinol. Metab.20079282977298310.1210/jc.2006‑200317504894
     [Google Scholar]
  22. RiddleM. FriasJ. ZhangB. MaierH. BrownC. LutzK. KoltermanO. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.Diabetes Care200730112794279910.2337/dc07‑058917698615
     [Google Scholar]
  23. SmithS.R. BlundellJ.E. BurnsC. ElleroC. SchroederB.E. KestyN.C. ChenK.S. HalsethA.E. LushC.W. WeyerC. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: A 6-wk translational research study.Am. J. Physiol. Endocrinol. Metab.20072932E620E62710.1152/ajpendo.00217.200717505051
     [Google Scholar]
  24. WeyerC. MaggsD. YoungA. KoltermanO. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control.Curr. Pharm. Des.20017141353137310.2174/138161201339735711472273
     [Google Scholar]
  25. KruseT. HansenJ.L. DahlK. SchäfferL. SensfussU. PoulsenC. SchleinM. HansenA.M.K. JeppesenC.B. Dornonville de la CourC. ClausenT.R. JohanssonE. FulleS. SkyggebjergR.B. RaunK. Development of cagrilintide, a long-acting amylin analogue.J. Med. Chem.20216415111831119410.1021/acs.jmedchem.1c0056534288673
     [Google Scholar]
  26. CaoJ BelousoffMJ JohnsonRM Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.Nat. Commun.202516338910.1038/s41467‑025‑58680‑y
     [Google Scholar]
  27. LauD.C.W. ErichsenL. FranciscoA.M. SatylganovaA. le RouxC.W. McGowanB. PedersenS.D. PietiläinenK.H. RubinoD. BatterhamR.L. Once-weekly cagrilintide for weight management in people with overweight and obesity: A multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.Lancet2021398103172160217210.1016/S0140‑6736(21)01751‑734798060
     [Google Scholar]
  28. EneboL.B. BerthelsenK.K. KankamM. LundM.T. RubinoD.M. SatylganovaA. LauD.C.W. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: A randomised, controlled, phase 1b trial.Lancet2021397102861736174810.1016/S0140‑6736(21)00845‑X33894838
     [Google Scholar]
  29. NordiskN. Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial.2024Available from: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915082
  30. CaoJ. BelousoffM.J. LiangY.L. JohnsonR.M. JosephsT.M. FletcherM.M. ChristopoulosA. HayD.L. DanevR. WoottenD. SextonP.M. A structural basis for amylin receptor phenotype.Science20223756587eabm960910.1126/science.abm960935324283
     [Google Scholar]
  31. dal MasoE. GlukhovaA. ZhuY. Garcia-NafriaJ. TateC.G. AtanasioS. ReynoldsC.A. Ramírez-AportelaE. CarazoJ.M. HickC.A. FurnessS.G.B. HayD.L. LiangY.L. MillerL.J. ChristopoulosA. WangM.W. WoottenD. SextonP.M. The molecular control of calcitonin receptor signaling.ACS Pharmacol. Transl. Sci.201921315110.1021/acsptsci.8b0005632219215
     [Google Scholar]
  32. LiangY.L. KhoshoueiM. RadjainiaM. ZhangY. GlukhovaA. TarraschJ. ThalD.M. FurnessS.G.B. ChristopoulosG. CoudratT. DanevR. BaumeisterW. MillerL.J. ChristopoulosA. KobilkaB.K. WoottenD. SkiniotisG. SextonP.M. Phase-plate cryo-EM structure of a class B GPCR–G-protein complex.Nature2017546765611812310.1038/nature2232728437792
     [Google Scholar]
  33. KeovP. ChristopoulosG. HickC.A. GlendorfT. Ballarín-GonzálezB. WoottenD. SextonP.M. Development of a novel assay for direct assessment of selective amylin receptor activation reveals novel differences in behavior of selective and nonselective peptide agonists.Mol. Pharmacol.2024105535937310.1124/molpharm.123.00086538458773
     [Google Scholar]
  34. SandraE. Amylin receptor subunit interactions are modulated by agonists and determine signaling.bioRxiv20242024.10.09.61748710.1101/2024.10.09.61748739416010
     [Google Scholar]
  35. GareljaM.L. WalkerC.S. HayD.L. CGRP receptor antagonists for migraine. Are they also AMY 1 receptor antagonists?Br. J. Pharmacol.2022179345445910.1111/bph.1558534076887
     [Google Scholar]
  36. CaoJ. BelousoffM.J. DanevR. ChristopoulosA. WoottenD. SextonP.M. Cryo-EM structure of the human amylin 1 receptor in complex with CGRP and Gs protein.Biochemistry20246391089109610.1021/acs.biochem.4c0011438603770
     [Google Scholar]
  37. MohamedK.E. LarsenA.T. MelanderS. AndersenF. KerrnE.B. KarsdalM.A. HenriksenK. The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection – A novel disease-modifying osteoarthritis drug.Arthritis Res. Ther.2024261129210.1186/s13075‑024‑03361‑238997785
     [Google Scholar]
  38. Gutiérrez-RojasI. LozanoD. Nuche-BerenguerB. MorenoP. AcitoresA. Ramos-ÁlvarezI. RoviraA. NovialsA. Martín-CrespoE. Villanueva-PeñacarrilloM.L. EsbritP. Amylin exerts osteogenic actions with different efficacy depending on the diabetic status.Mol. Cell. Endocrinol.2013365230931510.1016/j.mce.2012.11.01323178165
     [Google Scholar]
  39. MackC.M. SoaresC.J. WilsonJ.K. AthanacioJ.R. TurekV.F. TrevaskisJ.L. RothJ.D. SmithP.A. GedulinB. JodkaC.M. RolandB.L. AdamsS.H. LwinA. HerichJ. LaugeroK.D. VuC. PittnerR. PaternitiJ.R.Jr HanleyM. GhoshS. ParkesD.G. Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight.Int. J. Obes.201034238539510.1038/ijo.2009.23819935749
     [Google Scholar]
  40. FletcherM.M. KeovP. TruongT.T. MennenG. HickC.A. ZhaoP. FurnessS.G.B. KruseT. ClausenT.R. WoottenD. SextonP.M. AM833 is a novel agonist of calcitonin family G protein-coupled receptors: Pharmacological comparison to six selective and non-selective agonists.J. Pharmacol. Exp. Ther.2021377341744010.1124/jpet.121.00056733727283
     [Google Scholar]
  41. UdawelaM. ChristopoulosG. TilakaratneN. ChristopoulosA. AlbistonA. SextonP.M. Distinct receptor activity-modifying protein domains differentially modulate interaction with calcitonin receptors.Mol. Pharmacol.20066961984198910.1124/mol.105.02191516531504
     [Google Scholar]
  42. MackC.M. SmithP.A. AthanacioJ.R. XuK. WilsonJ.K. ReynoldsJ.M. JodkaC.M. LuM.G.W. ParkesD.G. Glucoregulatory effects and prolonged duration of action of davalintide: A novel amylinomimetic peptide.Diabetes Obes. Metab.201113121105111310.1111/j.1463‑1326.2011.01465.x21733060
     [Google Scholar]
  43. HaydockI. Takeda and Amylin take obesity combo forward as davalintide dropped.2010Available from: https://insights.citeline.com/SC007028/Takeda-and-Amylin-take-obesity-combo-forward-as-davalintide-dropped/
  44. GroganK. Takeda, Amylin excited about new obesity drug.2010Available from: https://pharmatimes.com/news/takeda_amylin_excited_about_new_obesity_drug_981755/
  45. A research study to see how well cagrisema helps people with excess body weight lose weight (REDEFINE 1); NCT05567796.2025Available from: https://clinicaltrials.gov/study/NCT05567796
  46. SilverwoodJ. Novo Nordisk takes a hit as CagriSema underperforms in weight loss.2024Available from: https://www.clinicaltrialsarena.com/news/novo-nordisk-takes-a-hit-as-cagrisema-underperforms-in-weight-loss/?cf-view
  47. A research study to see how well cagrisema helps people with type 2 diabetes and excess body weight lose weight (REDEFINE 2); NCT05394519.2025Available from: https://clinicaltrials.gov/study/NCT05394519
  48. AndreassenK.V. FeighM. HjulerS.T. GydesenS. HenriksenJ.E. Beck-NielsenH. ChristiansenC. KarsdalM.A. HenriksenK. A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats.Am. J. Physiol. Endocrinol. Metab.20143071E24E3310.1152/ajpendo.00121.201424801386
     [Google Scholar]
  49. LarsenA.T. SonneN. AndreassenK.V. GehringK. KarsdalM.A. HenriksenK. The dual amylin and calcitonin receptor agonist KBP-088 induces weight loss and improves insulin sensitivity superior to chronic amylin therapy.J. Pharmacol. Exp. Ther.20193701354310.1124/jpet.119.25757631028106
     [Google Scholar]
  50. LarsenA.T. SonneN. AndreassenK.V. KarsdalM.A. HenriksenK. The calcitonin receptor plays a major role in glucose regulation as a function of dual amylin and calcitonin receptor agonist therapy.J. Pharmacol. Exp. Ther.20203741748310.1124/jpet.119.26339232317372
     [Google Scholar]
  51. GydesenS. HjulerS.T. FrevingZ. AndreassenK.V. SonneN. HellgrenL.I. KarsdalM.A. HenriksenK. A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference.Br. J. Pharmacol.2017174759160210.1111/bph.1372328109166
     [Google Scholar]
  52. HenriksenK. BroekhuizenK. de BoonW.M.I. KarsdalM.A. BihletA.R. ChristiansenC. DillinghM.R. de KamM. KumarR. BurggraafJ. KamerlingI.M.C. Safety, tolerability and pharmacokinetic characterisation of DACRA KBP-042 in healthy male subjects.Br. J. Clin. Pharmacol.202187124786479610.1111/bcp.1492134019711
     [Google Scholar]
  53. Clinical trial results: A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of KBP-042 in patients with type 2 diabetes.2017Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001061-24/results
  54. Study to evaluate the efficacy and safety of KBP-042 in patients with type 2 diabetes; NCT03230786.2018Available from: https://clinicaltrials.gov/study/NCT03230786
  55. A clinical study to evaluate the safety, tolerability, PK, PD, and efficacy of KBP-089 in patients with T2DM; NCT03907202.2020Available from: https://clinicaltrials.gov/study/NCT03907202
  56. AndreassenK.V. LarsenA.T. SonneN. MohamedK.E. KarsdalM.A. HenriksenK. KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats.Mol. Metab.20215310128210.1016/j.molmet.2021.10128234214708
     [Google Scholar]
  57. SonneN. LarsenA.T. KarsdalM.A. HenriksenK. The impact of exposure profile on the efficacy of dual amylin and calcitonin receptor agonist therapy.Biomedicines20221010236510.3390/biomedicines1010236536289629
     [Google Scholar]
  58. MathiesenD.S. LundA. HolstJ.J. KnopF.K. LutzT.A. BaggerJ.I. THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin – physiology and pharmacology.Eur. J. Endocrinol.20221866R93R11110.1530/EJE‑21‑126135353712
     [Google Scholar]
  59. ZP 4982.2023Available from: https://adisinsight.springer.com/drugs/800045554
  60. SteinL.M. McGrathL.E. LhamoR. Koch-LaskowskiK. FortinS.M. SkarbalieneJ. Baader-PaglerT. JustR. HayesM.R. Mietlicki-BaaseE.G. The long-acting amylin/calcitonin receptor agonist ZP5461 suppresses food intake and body weight in male rats.Am. J. Physiol. Regul. Integr. Comp. Physiol.20213212R250R25910.1152/ajpregu.00337.202034259025
     [Google Scholar]
  61. Evaluation of safety and tolerability of single rising doses of BI 473494 in healthy subjects; NCT03195088.2022Available from: https://clinicaltrials.gov/study/NCT03195088
  62. BI 473494.2018Available from: https://adisinsight.springer.com/drugs/800049758
  63. Safety, tolerability, and clinical effects of petrelintide (ZP8396), a long-acting amylin analog.2024Available from: https://www.zealandpharma.com/media/vrypyzy1/zealand-pharma-at-obesity-week-2024.pdf
  64. Petrelintide.2024Available from: https://www.medchemexpress.com/petrelintide.html?locale=ko-KR
  65. OlsenMinna B. HövelmannUlrike GriffinJon KnudsenKim M. JohansenThue KendallDavid HeiseTim 92-LB: Safety, tolerability, and clinical effects of ZP8396, a novel long-acting amylin analog—A single ascending dose trial.Diabetes202372Supplement_192–LB10.2337/db23‑92‑LB
     [Google Scholar]
  66. Safety, tolerability, and clinical effects of ZP8396, an amylin analog: Multiple ascending dose trial.2023Available from: https://www.zealandpharma.com/media/eb1azc1d/zp8396-phase1-mad-part-1-obesityweek-2023.pdf
  67. A research study looking at the safety of multiple doses of ZP8396 and how it works in the body of healthy participants; NCT05613387.2024Available from: https://clinicaltrials.gov/study/NCT05613387
  68. Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide.2024Available from: https://www.globenewswire.com/news-release/2024/06/20/2901879/0/en/Zealand-Pharma-announces-positive-topline-results-from-the-Phase-1b-16-week-multiple-ascending-dose-clinical-trial-with-long-acting-amylin-analog-petrelintide.html
  69. GriffinJon HövelmannUlrike MelgaardAnita E. MacuraStanislava HammerMette JohansenThue 1668-P: Novel once-weekly amylin analog Petrelintide (ZP8396) is well tolerated with improved GI tolerability after multiple dosing.Diabetes202473Supplement_11668–P10.2337/db24‑1668‑P
     [Google Scholar]
  70. Roche strikes $5.3 billion amylin deal.Nat. Biotechnol.202543446046110.1038/s41587‑025‑02657‑140229374
     [Google Scholar]
  71. NiczeM. DecA. BorówkaM. KrzyżakD. BołdysA. BułdakŁ. OkopieńB. Molecular mechanisms behind obesity and their potential exploitation in current and future therapy.Int. J. Mol. Sci.20242515820210.3390/ijms2515820239125772
     [Google Scholar]
  72. NordiskN. Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity.2025Available from: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915251
  73. HornigoldD. Characterisation of AZD6234, a novel amylin receptor selective agonist peptide, in rodent models of weight loss and aversion.Available from: https://www.easd.org/media-centre/home.html%20#!resources/b-characterisation-of-azd6234-a-novel-amylin-receptor-selective-agonist-peptide-in-rodent-models-of-weight-loss-and-aversion-b
  74. A study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD6234 after repeat dose administration in participants who are overweight or obese.2023Available from: https://www.astrazenecaclinicaltrials.com/study/D8750C00002/
  75. Assess the safety, tolerability, and pharmacokinetics of AZD6234 following single ascending dose administration to healthy subjects who are overweight or obese; NCT05511025.2023Available from: https://clinicaltrials.gov/study/NCT05511025
  76. A study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD6234 after repeat dose administration in participants who are overweight or obese; NCT06132841.2025Available from: https://clinicaltrials.gov/study/NCT06132841
  77. A study in participants with obesity or overweight with at least one weight-related comorbidity (APRICUS); NCT06595238.2025Available from: https://clinicaltrials.gov/study/NCT06595238
  78. Gubra announces positive GUBamy Phase 1 SAD data.2024Available from: https://www.gubra.dk/mfn_news/gubra-announces-positive-gubamy-phase-1-sad-data/
  79. A two-part first-in-human study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GUB014295.2025Available from: https://clinicaltrials.gov/study/NCT06144684
  80. Eloralintide.2025Available from: https://synapse.patsnap.com/drug/30ab69e9d8ca47bba5338d6c29cd266f
  81. Eloralintide by Eli Lilly and Co for Obesity: Likelihood of Approval.2024Available from: https://www.pharmaceutical-technology.com/data-insights/eloralintide-eli-lilly-and-co-obesity-likelihood-of-approval/
  82. Eloralintide (Synonyms: LY-3841136).2025Available from: https://www.medchemexpress.com/eloralintide.html?srsltid=AfmBOorh-DoVEJBsO74wFTBIeGQ94wW7EArizVOfIVfReL4s5LVzH-gB
  83. A study of LY3841136 compared with placebo in adult participants with obesity or overweight; NCT06230523.2025Available from: https://clinicaltrials.gov/study/NCT06230523
  84. LillyE. A study of LY3841136 compared with placebo in adult participants with obesity or overweight.2025Available from: https://trials.lilly.com/en-US/trial/454455
    [Google Scholar]
  85. A study of LY3841136 in overweight and obese participants; NCT06345066.2025Available from: https://clinicaltrials.gov/study/NCT06345066
  86. LillyE. A study of LY3841136 in overweight and obese participants.2024Available from: https://trials.lilly.com/en-US/trial/471555
    [Google Scholar]
  87. A study of LY3841136 in Japanese participants with obesity or overweight; NCT06297616.2025Available from: https://clinicaltrials.gov/study/NCT06297616
  88. A study to investigate weight management with LY3841136 and tirzepatide (LY3298176), alone or in combination, in adult participants with obesity or overweight with type 2 diabetes; NCT06603571.2025Available from: https://clinicaltrials.gov/study/NCT06603571
  89. LeeS. Development of the novel amylin and calcitonin receptor activators by peptide mutagenesis.Arch. Biochem. Biophys.202476211019110.1016/j.abb.2024.11019139481742
     [Google Scholar]
  90. LeeS. Modulation of amylin and calcitonin receptor activation by hybrid peptides.Peptides202418217131410.1016/j.peptides.2024.17131439454962
     [Google Scholar]
  91. WanQ. OkashahN. InoueA. NehméR. CarpenterB. TateC.G. LambertN.A. Mini G protein probes for active G protein–coupled receptors (GPCRs) in live cells.J. Biol. Chem.2018293197466747310.1074/jbc.RA118.00197529523687
     [Google Scholar]
  92. EnglandC.G. EhlerdingE.B. CaiW. NanoLuc: A small luciferase is brightening up the field of bioluminescence.Bioconjug. Chem.20162751175118710.1021/acs.bioconjchem.6b0011227045664
     [Google Scholar]
  93. LeeM.F. PohC.L. Strategies to improve the physicochemical properties of peptide-based drugs.Pharm. Res.202340361763210.1007/s11095‑023‑03486‑036869247
     [Google Scholar]
  94. JamaluddinA. ChuangC.L. WilliamsE.T. SiowA. YangS.H. HarrisP.W.R. PetersenJ.S.S.M. BowerR.L. ChandS. BrimbleM.A. WalkerC.S. HayD.L. LoomesK.M. Lipidated calcitonin gene-related peptide (CGRP) peptide antagonists retain CGRP receptor activity and attenuate CGRP action in vivo. Front. Pharmacol.20221383258910.3389/fphar.2022.83258935341216
     [Google Scholar]
  95. KnudsenL.B. LauJ. The discovery and development of liraglutide and semaglutide.Front. Endocrinol.20191015510.3389/fendo.2019.0015531031702
     [Google Scholar]
  96. WildingJ.P.H. BatterhamR.L. CalannaS. DaviesM. Van GaalL.F. LingvayI. McGowanB.M. RosenstockJ. TranM.T.D. WaddenT.A. WhartonS. YokoteK. ZeuthenN. KushnerR.F. Once-weekly semaglutide in adults with overweight or obesity.N. Engl. J. Med.202138411989100210.1056/NEJMoa203218333567185
     [Google Scholar]
  97. McLatchieL.M. FraserN.J. MainM.J. WiseA. BrownJ. ThompsonN. SolariR. LeeM.G. FoordS.M. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor.Nature1998393668333333910.1038/306669620797
     [Google Scholar]
  98. HayD.L. GareljaM.L. PoynerD.R. WalkerC.S. Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25.Br. J. Pharmacol.2018175131710.1111/bph.1407529059473
     [Google Scholar]
  99. OgunlajaO.I. GoadsbyP.J. Headache: Treatment update.eNeurologicalSci20222910042010.1016/j.ensci.2022.10042036636337
     [Google Scholar]
  100. GareljaM.L. AlexanderT.I. BennieA. NimickM. PetersenJ. WalkerC.S. Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors.Br. J. Pharmacol.2023112110.1111/bph.1621837580864
     [Google Scholar]
  101. PanK.S. SiowA. HayD.L. WalkerC.S. Antagonism of CGRP signaling by rimegepant at two receptors.Front. Pharmacol.202011124010.3389/fphar.2020.0124032973499
     [Google Scholar]
  102. GhanizadaH. Al-KaragholiM.A.M. WalkerC.S. ArngrimN. ReesT. PetersenJ. SiowA. Mørch-RasmussenM. TanS. O’CarrollS.J. HarrisP. SkovgaardL.T. JørgensenN.R. BrimbleM. WaiteJ.S. ReaB.J. SowersL.P. RussoA.F. HayD.L. AshinaM. Amylin analog pramlintide induces migraine-like attacks in patients.Ann. Neurol.20218961157117110.1002/ana.2607233772845
     [Google Scholar]
/content/journals/cdt/10.2174/0113894501398624250819070004
Loading
A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy
Curr Drug Targets 26, 980 (2025); https://doi.org/10.2174/0113894501398624250819070004
/content/journals/cdt/10.2174/0113894501398624250819070004
/content/journals/cdt/10.2174/0113894501398624250819070004
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): affinity; Amylin; calcitonin; obesity; peptide hormone; potency

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test